Panel Discussion: Who Are the High-Risk CKD Patients Now? Redefining Risk Beyond Proteinuria
- Understanding what is the unmet need on top of standard of care and treatment landscape Combinations & Polypharmacy?
- Are traditional definitions of high risk (low eGFR, proteinuria) still sufficient in the era of multi-omics and cardiometabolic overlap?
- What biomarkers and surrogate endpoints are emerging to identify and serve non-proteinuric CKD patients?
- How can we define clinical endophenotypes, such as patients with reduced ejection fraction, diabetes, or obesity—that may signal higher risk or non-response?
- What data are missing from current longitudinal cohorts (e.g., cardiovascular outcomes, repeat biopsies), and how do we fill these gaps to better guide drug development?